NZ's PHARMAC proposal to award sole supply to Zoladex and reference price leuprorelin

7 July 2016
pharmac-big

Following a Request for Proposals (RFP) for the supply of gonadotropin-releasing hormone analogues (GnRH analogues), issued in March 2016, New Zealand’s Pharmaceutical Management Agency, PHARMAC, has entered into a provisional agreement with the local subsidiary of Anglo-Swedish pharma major AstraZeneca (LSE: AZN) over a cancer drug.

PHARMAC is seeking feedback on a proposal to:

  • reduce the price and subsidy for AstraZeneca’s brand of goserelin (Zoladex) from October 1, 2016.
  • award Sole Supply Status and Hospital Supply Status to AstraZeneca’s brand of goserelin from December 1, 2016.
    • This means Zoladex would be the only fully funded brand of goserelin in the community and would be the only available brand in District Health Board (DHB) hospitals subject to a 1% discretionary variance (DV) limit from December 1, 2016.
  • reduce the subsidy for other listed GnRH analogues listed in Section B of the Pharmaceutical Schedule to the level of subsidy of goserelin (Reference Pricing) as soon as October 1, 2016.
    • If the suppliers of leuprorelin do not reduce the price to the level of subsidy for goserelin, this would result in:
      • A patient part charge applying to leuprorelin medicines; and
      • goserelin being the only fully funded GnRH analogue on the Pharmaceutical Schedule.
  • delist the four-monthly dose presentation of leuprorelin – leuprorelin Inj 30mg, prefilled syringe (Eligard) from October 1, 2016.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical